Remix Therapeutics’ $70 Million Series B Financing

Gunderson Dettmer advised Remix Therapeutics on the deal.

Remix Therapeutics, a Massachusetts-based biotech company, announced its $70 million Series B financing which included participation from Surveyor, Foresite Capital, Atlas Ventures, The Column Group, Arch Venture Partners, Alexandria Venture Investments, and Casdin Capital. Remix Therapeutics focuses on developing novel small molecule therapies designed to reprogram RNA processing and treat diseases in new ways. The new capital will enable the company to support development of its REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

The Gunderson deal team was led by Tim Ehrlich (Picture) and included David Horne, Graham Rogers, Alexandra Noymer, Aliya Sanders and Carson Heyer.

Involved fees earner: Timothy Ehrlich – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; Carson Heyer – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; David Horne – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; Alexandra Noymer – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; Graham Rogers – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; Aliya Sanders – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;

Law Firms: Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;

Clients: Remix Therapeutics;

Martina Bellini

Author: Martina Bellini